Lonidamine

Lonidamine

Clinical data
ATC code	L01XX07 (WHO)
Identifiers
IUPAC name 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid
JSmol)	Interactive image
SMILES C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O
InChI InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21) N Key:WDRYRZXSPDWGEB-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Lonidamine is a derivative of

Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. This is due to its proven ability to inhibit energy metabolism in cancer cells, and to enhance the activity of anticancer agents.[1]

Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide.^[2] An in-vitro study showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.^[2]

A derivative of lonidamine,